TrialBMJ open2020

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.

Lisa A de Jong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.